TD Cowen analyst Ritu Baral has maintained their bullish stance on ANRO stock, giving a Buy rating yesterday.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ritu Baral has given her Buy rating due to a combination of factors that highlight Alto Neuroscience, Inc.’s promising future prospects. The company is preparing to initiate a Phase 2b study for its innovative treatment, ‘207, which combines pramipexole and ondansetron, in the first half of 2026. This treatment is designed to enhance the dosing capabilities and mitigate adverse effects associated with pramipexole, thereby potentially increasing its therapeutic efficacy.
Furthermore, Alto Neuroscience, Inc. has a strong financial position, with a cash runway that supports operational expenses into 2028. The company’s strategic acquisition of dopamine agonist drug combinations and the positive reception from key opinion leaders regarding pramipexole’s potential in treating treatment-resistant depression contribute to the optimistic outlook. These elements combined suggest a solid probability of success for the company’s upcoming trials and overall growth, justifying the Buy rating.
According to TipRanks, Baral is a top 100 analyst with an average return of 34.9% and a 56.94% success rate. Baral covers the Healthcare sector, focusing on stocks such as Palvella Therapeutics, ACADIA Pharmaceuticals, and Milestone Pharmaceuticals.
In another report released yesterday, Jefferies also maintained a Buy rating on the stock with a $25.00 price target.